Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
UNIVERSITE D'AIX-MARSEILLE operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio features 1 pending office action. This matter is handled by the distinct examiner, suggesting a highly centralized prosecution strategy. Such a focused approach allows for a direct line of communication with the USPTO during the review process.
The busiest examiner identified in the data is MIDDLETON, DANAYA L, who is responsible for the pending office action. Because this individual manages the entire active workload, the company's immediate patent prospects are tied to the specific examination style of MIDDLETON, DANAYA L. Practitioners must tailor their arguments to the specific technical standards favored by this examiner.
The prosecution is also confined to 1 distinct art unit. This concentration indicates that the technical scope of the pending intellectual property is limited to a specific niche within the Biotechnology & Pharmaceuticals field. Operating within a single art unit reduces the complexity of managing disparate procedural requirements that often arise when a portfolio spans multiple examination groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | MIDDLETON, DANAYA L | 10d overdue |
| 17282491 | METHODS AND SYSTEMS FOR CONTROLLING THE AGONISTIC PROPERTIES OF ANTIBODY VARIABLE DOMAINS BY LIGHT | ROONEY, NORA MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | MIDDLETON, DANAYA L | 10d overdue |
| 17282491 | METHODS AND SYSTEMS FOR CONTROLLING THE AGONISTIC PROPERTIES OF ANTIBODY VARIABLE DOMAINS BY LIGHT | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17282491 | METHODS AND SYSTEMS FOR CONTROLLING THE AGONISTIC PROPERTIES OF ANTIBODY VARIABLE DOMAINS BY LIGHT | ROONEY, NORA MAUREEN | 1641 | §103§112Other | Non-Final OA | — | Pending | Apr 02, 2021 |
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | MIDDLETON, DANAYA L | 1674 | §103§112 | Non-Final OA | 10d overdue | Pending | Sep 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial